To explore the curative effect and safety of Risperidone，aripiprazole，sodium valproate，modified electroconvulsive therapy(MECT), or Magnetic seizure therapy(MST) with Clozapine in the treatment of treatment-resistant schizophrenia， and to provide the basis for clinical medication.
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The diagnosis of schizophrenia according to DSM-V
18～60 years old
2 prior failed treatment trials with 2 different antipsychotics at doses of at least 600 mg/day chlorpromazine equivalents, each of at least 6 weeks duration;
Signed an informed consent
You may not be if
patients to be diagnosed according to DSM-V for substance abused, development delayed
suffering from serious physical disease and can not accept the treatment
MST contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure
allergic to risperidone ,aripiprazole, or sodium valproate
Participated in any clinical subject within 30 days
Pregnancy or lactation
Clareo Health | The Optimal Treatment for Treatment-resistant Schizophrenia
